» Articles » PMID: 24122750

Prognostic Role of Neutrophil-to-lymphocyte Ratio in Colorectal Cancer: a Systematic Review and Meta-analysis

Overview
Journal Int J Cancer
Specialty Oncology
Date 2013 Oct 15
PMID 24122750
Citations 235
Authors
Affiliations
Soon will be listed here.
Abstract

The prognostic role of inflammation index like neutrophil-to-lymphocyte ratio (NLR) in colorectal cancer (CRC) remains controversial. We conduct a meta-analysis to determine the predictable value of NLR in the clinical outcome of CRC patients. The analysis was carried out based on the data from 16 studies (19 cohorts) to evaluate the association between NLR and overall survival (OS) and progression-free survival (PFS) in patients with CRC. In addition, the relationship between NLR and clinicopathological parameters was assessed. Hazard ratio (HR) or odds ratio (OR) with its 95% confidence interval (CI) was used as the effect size estimate. Our analysis results indicated that elevated pretreatment NLR predicted poorer OS (HR: 1.813, 95% CI: 1.499-2.193) and PFS (HR: 2.102, 95% CI: 1.554-2.843) in patients with CRC. Increased NLR is also significantly associated with the poorer differentiation of the tumor (OR: 1.574, 95% CI: 1.226-2.022) and higher carcino-embryonie antigen (CEA) level (OR: 1.493, 95% CI: 1.308-1.705). By these results, we conclude that NLR gains a prognostic value for patients with CRC. NLR should be monitored in CRC patients for rational stratification of the patients and adjusting the treatment strategy.

Citing Articles

Preoperative predictors of concurrent endometrial carcinoma in patients with endometrial intraepithelial neoplasia: the role of HALP score and other inflammatory markers.

Aytekin O, Karagoz C, Goktas E, Tokalioglu A, Tiryaki Guner G, Ozkaya Ucar Y J Turk Ger Gynecol Assoc. 2025; 26(1):34-40.

PMID: 40077970 PMC: 11905214. DOI: 10.4274/jtgga.galenos.2025.2024-12-5.


Pan‑immune‑inflammatory values predict survival in patients after radical surgery for non‑metastatic colorectal cancer: A retrospective study.

Li K, Zeng X, Zhang Z, Wang K, Pan Y, Wu Z Oncol Lett. 2025; 29(4):197.

PMID: 40046636 PMC: 11880885. DOI: 10.3892/ol.2025.14943.


Effects of Diverting Stoma Creation in Minimally Invasive Surgery for Rectal Cancer.

Momose H, Takahashi M, Kawai M, Sugimoto K, Takahashi H, Motegi S J Anus Rectum Colon. 2025; 9(1):88-94.

PMID: 39882218 PMC: 11772786. DOI: 10.23922/jarc.2024-047.


Prognostic significance of peripheral blood biomarkers in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab-a polish multicenter, observational study.

Pacholczak-Madej R, Drobniak A, Grela-Wojewoda A, Calik J, Viegas N, Tusien-Malecka D Clin Exp Med. 2025; 25(1):45.

PMID: 39849293 PMC: 11759459. DOI: 10.1007/s10238-024-01544-4.


Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.

Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K Cancer Med. 2025; 14(2):e70618.

PMID: 39840727 PMC: 11751879. DOI: 10.1002/cam4.70618.